Toluene, Xylene, Trichloroethylene 투여가 흰쥐의 시상하부와 뇌하수체의 GnRH, GnRH Receptor, Pit-1 유전자 발현에 미치는 영향

기노석,이종태,강대성,김대환,이채관,이헌,전진호,김정호,이채언 大韓産業醫學會 1998 대한직업환경의학회지 Vol.10 No.2

The workplace exposure of chemicals has steadily increased, therefore the concern for subsequent effect on reproductive outcome has been an important issue in occupational medicine. In previous studies, higher rates of spontaneous abortion, reduced fertility and menstrual disorder among women, and an impairement of sperm quantity and quality among men have been associated with a wide variety of chemical agents. This study was conducted to evaluate the effects of toluene, xylene and trichloroethylene(TCE) injection on the mRNA levels of GnRH, GnRH receptor and Pit-1 genes in male rats hypothalamus and pituitary and the effects on the plasma levels of FSH, LH, prolactin and testosterone. Sprague-Dawley male rats were divided into five groups of five each according to concentration of toluene, xylene and TCE. The rats were injected subcutaneously to 0, 50, 100, 200, 400 mg/kg body weight/day of toluene, xylene and TCE, respectively for 6 days. Rat brains were excised and hypothalamus and pituitary were separated. Reverse transcription-polymerase chain reaction (RT-PCR) and RNase protection assay(RPA) were used to evaluate the GnRH, GnRH receptor and Pit-1 mRNA levels. Plasma concentrations of FSH, LH, prolactin and testosterone were assayed by radioimmunoassay(RIA). The results were as follows; 1. GnRH, GnRH receptor and Pit-1 mRNA levels in toluene and xylene injected groups, and GnRH receptor mRNA levels in TCE injected group were lowered dose-dependently. Especially, GnRH receptor and Pit-1 mRNA levels in 200mg/kg of toluene injected group, and GnRH, GnRH receptor and Pit-1 mRNA levels in 400mg/kg of toluene injected group were significantly lower than control group (p<0.05). GnRH receptor and Pit-1 mRNA levels in 400mg/kg of xylene injected group, and GnRH receptor mRNA levels in 400mg/kg of TCE injected group were significantly lower than control group(p<0.05). 2. The plasma levels of prolactin and testosterone in 400mg/kg of toluene injected group, and LH in 100, 200 and 400mg/kg of xylene injected group, and testosterone in 400 mg/kg of TCE injected group were significantly lower than control group(p<0.05). In conclusion, we speculated that toluene and xylene affected reproductive system secondarily through hypothalamus-pituitary axis, and TCE affected directly through steroidogenesis. And we recommended that further study for assessment of the reproductive toxicity of mixed organic solvent exposures should be conducted.

Magnetically-separable and highly-stable enzyme system based on crosslinked enzyme aggregates shipped in magnetite-coated mesoporous silica

Lee, Jinwoo,Na, Hyon Bin,Kim, Byoung Chan,Lee, Jin Hyung,Lee, Byoungsoo,Kwak, Ja Hun,Hwang, Yosun,Park, Je-Geun,Gu, Man Bock,Kim, Jaeyun,Joo, Jin,Shin, Chae-Ho,Grate, Jay W.,Hyeon, Taeghwan,Kim, Jungb Royal Society of Chemistry 2009 Journal of materials chemistry Vol.19 No.42

<P>A magnetically-separable and highly-stable enzyme system was developed by adsorption of enzymes in superparamagnetic hierarchically ordered mesocellular mesoporous silica (M-HMMS) and subsequent enzyme crosslinking. Superparamagnetic nanoparticles were homogeneously incorporated into hierarchically-ordered mesocellular mesoporous silica (HMMS) by the decomposition of a preformed iron propionate complex. The size of the incorporated superparamagnetic nanoparticles was around 5 nm, generating a magnetically separable host with high pore volumes and large pores (M-HMMS). α-chymotrypsin (CT) was adsorbed into M-HMMS with high loading (∼30 wt%) in less than 30 minutes. Glutaraldehyde (GA) treatment of adsorbed CT resulted in nanometer scale crosslinked enzyme aggregates in M-HMMS (CLEA-M). The activity of these CT aggregates in M-HMMS (CLEA-M-CT) was 34 times than that of simply adsorbed CT in M-HMMS, due to an effective prevention of enzyme leaching during washing <I>via</I> a ship-in-a-bottle approach. CLEA-M-CT maintained the initial activity not only under shaking (250 rpm) for 30 days, but also under recycled uses of 35 times. The same approach was employed for the synthesis of CLEA-M of lipase (CLEA-M-LP), and proven to be effective in improving the loading, activity, and stability of enzyme when compared to those of adsorbed LP in M-HMMS.</P> <P>Graphic Abstract</P><P>Crosslinked enzyme aggregates in magnetitie-coated mesoporous silica, fabricated <I>via</I> a two-step procedure of enzyme adsorption and crosslinking, were highly active, highly stable, and easily recyclable using a magnet. <IMG SRC='http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=b909109b'> </P>

A case of monocytic Leukemia cutis

Chae Young Lee,Ki Yeol Lee,Kyu Won Choi,Young Hun Kim,Ki Ho Kim 대한피부과학회 2009 대한피부과학회 학술발표대회집 Vol.61 No.1

정신분열병에 대한 리스페리돈의 효과 및 안정성

이민수,김용구,김영훈,연병길,오병훈,윤도준,윤진상,이철,정희연,강병조,김광수,김동언,김명정,김상훈,김희철,나철,노승호,민경준,박기창,박두병,백기청,백인호,손봉기,손진욱,양병환,양창국,우행원,이정호,이종범,이홍식,임기영,전태연,정영조,정영철,정인과,정인원,지익성,채정호,한상익,한선호,한진희,서광윤 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.1

연구목적 : 본 시험의 목적은 임상시험 시작전에 연구자들을 대상으로 PANSS Workshop을 통하여 PANSS, ESRS에 대한 국내에서의 표준화 작업을 구축하고 새로운 정신병 치료제인 리스페리돈의 효과와 안정성을 재확인하여 리스페리돈 사용에 대한 적정화를 이루는데 있다. 연구방법 : 1996년 4월부터 1996년 9월까지 국내 39개 대학병원 정신과에 입원중인 혹은 증상이 악화되어 입원하는 정신분열병 환자 377명을 대상으로 다시설 개방 연구를 시행하였다. 1주일간의 약물 배설기간을 가진후, 리스페리돈을 8주간 투여하였고, 기준점, 1주, 2주, 4주, 그리고 8주후에 평가되었다. 용량은 제1일에는 리스페리돈 1mg씩 1일 2회, 제2일에는 2mg씩 1일 2회, 제3∼7일에는 3mg씩 1일 2회 투여하였다. 이후 환자의 임상상태에 따라 임의로 증량할 수 있으며, 최대 일일 16mg을 초과하지 않도록 하였다. 추체외로 증상을 조절하기 위한 투약을 허용하였다. 임상증상 및 부작용의 평가는 PANSS(Positive and Negative Syndrome Scale), CGI(Clinical Global Impression) 그리고 ESRS(Extrapyramidal Symptom Rating Scale)을 사용하였다. 연구결과 : 377명중 343명(91%)이 8주간의 연구를 완결하였다. 치료 종결시점인 8주후 PANSS 총점수가 20% 이상 호전된 경우를 약물 반응군으로 정의할때, 약물반응군은 81.3%였다. 리스페리돈에 반응하는 예측인자로는 발병연령, 이전의 입원 횟수, 유병기간이 관련 있었다. 리스페리돈은 1주후부터 PANSS양성, 음성, 및 일반정신병리 점수상에 유의한 호전을 보여 효과가 빨랐다. CGI의 경우도 기준점에 비해 1주후부터 유의한 감소를 나타내었다. ESRS의 경우, 파킨슨 평가점수는 기준점과 비교해 투여 1주, 2주, 4주후 유의하게 증가되었다가 8주후 기준점과 차이가 없었다. Dystonia 평가점수는 1주후만 유의한 증가를 보였으며, dyskinesia 평가점수는 유의한 차이가 없었다. 혈압, 맥박수의 생명징후 및 일반 혈액학 검사, 생화학적 검사, 심전도 검사에서 유의한 변화는 없었다. 결 론 : 이상의 다시설 개방 임상 연구를 통해 리스페리돈은 정신분열병 환자에서 양성증상뿐만 아니라 음성증상 및 전반적인 증상에도 효과적인 것으로 사료된다. 보다 명확한 평가를 위해서는 다른 항정신병약물과의 이중맹검 연구가 필요할 것으로 생각되며, 또한 장기적 치료에 대한 평가도 함께 이루어져야 하겠다. Objective : The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method : This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points ; at baseline, and 1, 2, 4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results : 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action ; a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. Conclusions : This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.

Risk factors of ocular involvement in children with mitochondrial respiratory chain complex defect

Chae, Jung-Hyun,Lee, Jung-Hun,Kim, Kyo-Ryung,Byeon, Suk-Ho,Lee, Young-Mock,Kang, Hoon-Chul,Lee, Joon-Soo,Kim, Heung-Dong The Korean Pediatric Society 2010 Clinical and Experimental Pediatrics (CEP) Vol.53 No.12

Purpose: Mitochondrial dysfunction can present with various symptoms depending on the organ it has affected. This research tried to analyze the ophthalmologic symptoms and ophthalmologic examination (OE) results in patients with mitochondrial disease (MD). Methods: Seventy-four patients diagnosed with mitochondrial respiratory chain complex defect with biochemical enzyme assay were included in the study. They were divided into 2 groups based on the OE results by funduscopy and were analyzed on the basis of their clinical features, biochemical test results, morphological analysis, and neuroimaging findings. Results: Thirty-seven (50%) of the 74 MD patients developed ophthalmologic symptoms. Abnormal findings were observed in 36 (48.6%) patients during an OE, and 16 (21.6%) of them had no ocular symptoms. Significantly higher rates of prematurity, clinical history of epilepsy or frequent apnea events, abnormal light microscopic findings in muscle pathology, diffuse cerebral atrophy in magnetic resonance imaging, and brainstem hyperintensity and lactate peaks in magnetic resonance spectroscopy were noted in the group with abnormal OE results. Conclusion: Although the ophthalmologic symptoms are not very remarkable in MD patients, an OE is required. When the risk factors mentioned above are observed, a more active approach should be taken in the OE because a higher frequency of ocular involvement can be expected.

Complete mitochondrial genome of the invasive semi-aquatic mammal, nutria Myocastor coypus (Rodentia; Myocastoridae)

Lee, Do-Hun,Lee, Moo-Seung,Kim, Young-Chae,Kim, Il Ryong,Kim, Hye Kwon,Jeong, Dae Gwin,Lee, Jung Ro,Kim, Ji Hyung Springer-Verlag 2018 Conservation genetics resources Vol.10 No.4

Osteomyelitis Caused by Hypervirulent Klebsiella pneumoniae : The First Korean Case With Family Spread

Lee Chang-Hun,Chae Jeong Don,Choe Wonho,Lee Hyo Young,Sohn Yong-Hak,Ihm Chunhwa,Jeong Ji Hun 대한진단검사의학회 2021 Annals of Laboratory Medicine Vol.41 No.2

<i>Eimeria</i> species in cattle with diarrhoea in the Republic of Korea regarding age, season and nature of diarrhoea

Lee, Seung-Hun,Kim, Ha-Young,Lee, Haeseung,Kim, Jong Wan,Lee, Yu-Ran,Chae, Myeong Ju,Oh, Sang-Ik,Kim, Jong Ho,Rhee, Man Hee,Kwon, Oh-Deog,Goo, Youn-Kyoung,Kim, Tae-Hwan,Geraldino, Paul John L,Kwak, Do BMJ Group Group Ltd 2018 The Veterinary record Vol.183 No.16

<P>This study evaluated the prevalence of <I>Eimeria</I> species, particularly <I>E bovis</I>, <I>E zuernii</I> and <I>E auburnensis</I> that are pathogenic to cattle, in faecal samples collected from cattle with diarrhoea reared in the Republic of Korea by using microscopy and PCR. In addition, the prevalence of <I>Eimeria</I> species was analysed according to age, type of cattle, region, season and nature of diarrhoea. Overall, <I>Eimeria</I> species were identified in 279 of the 1261 (22.1 per cent) faecal samples through microscopy, and statistical analysis revealed a lower prevalence in calves aged than three weeks or less and higher prevalence in cattle with haemorrhagic diarrhoea. Of the 279 microscopy-positive samples, <I>E bovis</I>, <I>E zuernii</I> and <I>E auburnensis</I> were identified in 100 (7.9 per cent), 83 (6.6 per cent) and 27 (2.1 per cent) faecal samples, respectively, by using PCR. To the authors' knowledge, this study is the first to apply PCR for epizootiology of bovine coccidiosis.</P>

A case of monocytic Leukemia cutis (초)

( Chae Young Lee ),( Ki Yeol Lee ),( Kyu Won Choi ),( Young Hun Kim ),( Ki Ho Kim ) 대한피부과학회 2009 초록집 Vol.47 No.10

Influence of obesity and metabolic syndrome on clinical outcomes of ST-segment elevation myocardial infarction in men undergoing primary percutaneous coronary intervention

Lee, Seung Hun,Jeong, Myung Ho,Kim, Ju Han,Kim, Min Chul,Sim, Doo Sun,Hong, Young Joon,Ahn, Youngkeun,Chae, Shung Chull,Seong, In Whan,Park, Jong Sun,Chae, Jei Keon,Hur, Seung Ho,Cha, Kwang-Soo,Kim, H Elsevier 2018 Journal of cardiology Vol.72 No.4

<P><B>Abstract</B></P> <P><B>Background</B></P> <P>The correlation between obesity and metabolic syndrome (MetS) and its impact on cardiovascular disease remains unclear. This study aims to investigate the impact of metabolic status and obesity on clinical outcomes of male patients with ST-segment elevation myocardial infarction (STEMI).</P> <P><B>Methods</B></P> <P>Data from the Korea Acute Myocardial Infarction Registry-National Institutes of Health registry were used to evaluate the impact of obesity and MetS on patients undergoing primary percutaneous coronary intervention (PPCI) from November 2005 to November 2015. Patients were grouped according to the presence or absence of obesity and MetS (‘obese−/MetS−’, ‘obese−/MetS+’, ‘obese+/MetS−’, or ‘obese+/MetS+’, respectively). All-cause death and major adverse cardiac events (MACE) were recorded during 12 months of follow-up.</P> <P><B>Results</B></P> <P>A total of 14,357 patients were included. Multivariate analysis showed that the presence of MetS was an independent risk factor for all-cause death (HR 2.08, 95% CI 1.30–3.31, <I>p</I> =0.002) and cardiovascular death (HR 2.44, 95% CI 1.33–4.46, <I>p</I> =0.004) at 12 months among normal weight patients. The protective effect of obesity was observed, compared with the obese−/MetS+ group, in terms of all-cause death (HR 0.50, 95% CI 0.31–0.81, <I>p</I> =0.005) and cardiovascular death (HR 0.52, 95% CI 0.28–0.96, <I>p</I> =0.038; vs. total obese individuals), but it might have disappeared compared with the obese−/MetS− group. The rate of MACE did not differ significantly according to category by obesity and MetS.</P> <P><B>Conclusions</B></P> <P>The obesity paradox has not been observed between obese and normal weight patients without MetS. Risk stratification on the basis of the presence or absence of MetS is not a clinically useful indicator of outcome in obese male patients with STEMI after PPCI.</P> <P><B>Highlights</B></P> <P> <UL> <LI> About a third of obese ST-elevation myocardial infarction (STEMI) patients were metabolically healthy. </LI> <LI> Presence of MetS was not associated with poor prognosis during 12 months after PPCI. </LI> <LI> Risk stratification by MetS was not useful for obese STEMI patients. </LI> <LI> DES and statins are beneficial in obese STEMI individuals independent of MetS status. </LI> </UL> </P>